Compare Northrop Grumman Corporation (NOC) vs TG Therapeutics Inc (TGTX) Price & Performance

Northrop Grumman (NOC) trades at $577.11, down 0.13% on the day, with a bullish technical trend supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with a record $105 billion backlog, driven by defense contracts like the Sentinel program. Fundamentals show solid profitability with a 10.48% net income margin and 26.96% ROE, though valuation ratios like P/E of 18.3 are moderate. Recent news highlights a $3 billion missile-interceptor agreement, reinforcing growth prospects.

Outlook remains positive with analyst consensus favoring Buy (57% of ratings) and a $598.57 price target, implying ~4% upside. Key opportunities include sustained defense spending and backlog execution, while risks involve margin pressures from specific programs and geopolitical dependencies. The stock's proximity to its 52-week high suggests cautious optimism amid robust operational performance.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.